Commentary on: Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-blind, Placebo-controlled Trial.

Related Articles

Commentary on: Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-blind, Placebo-controlled Trial.

Urology. 2013 May 2;

Authors: Black P

PMID: 23642941 [PubMed - as supplied by publisher]

Dalcetrapib ic50 selleck chemical BAY80-6946 selleckchem BAY80-6946 selleck chemical